See all news

STAAR Surgical Reports Record Second Quarter Results for Total Revenue, ICL Sales and ICL Units

  • 2019-07-31
  • Press release


LAKE FOREST, Calif.--(BUSINESS WIRE)--Jul. 31, 2019-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended June 28, 2019.

Second Quarter 2019 Overview

  • Net Sales of $39.7 Million (Up 17%) as Reported and $40.3 Million (Up 19%) Constant Currency from the Prior Year Quarter
  • ICL Sales of $34.4 Million (Up 26%) as Reported and $34.9 Million (Up 28%) Constant Currency from the Prior Year Quarter
  • ICL Units Up 34% from the Prior Year Quarter
  • Gross Margin at 75.4% Up 100 Basis Points from the Prior Year Quarter
  • Net Income of $0.08 per Share vs. Prior Year Quarter Net Income of $0.04 per Share
  • Cash and Cash Equivalents Ended the Quarter at $103.3 Million.

“The record second quarter 2019 results we reported today represent excellent progress for STAAR Surgical as we target paradigm change in refractive vision correction with our family of proprietary Collamer® lenses. Growth metrics in the second quarter for ICL Sales, Units, Gross Margin, Operating Margin and GAAP EPS were all up meaningfully as compared to our breakout financial results in the year ago period. When coupled with a solid first quarter, we believe our second quarter results put us firmly on track to achieve or exceed our full year targets for 30% ICL unit growth, 20% company revenue growth, achievement of year-over-year improvements in GAAP net income, positive cash flow generation and a higher level of cash on our balance sheet,” said 

Caren Mason, President and CEO of STAAR Surgical. “Our ICL units were up 34% in the second quarter over the prior year period with growth of 48% in China, 43% in consolidated smaller APAC markets, 42% in Korea, 29% in Japan, 22% in India, 12% in Spain and 10% in Latin America. Importantly, in concert with record top line growth, key operating and financial metrics were strong during the second quarter with expanding margins, a doubling of our GAAP net income profitability and meaningful cash generation from operations. Subsequent to the end of the quarter we also took actions to advance our pipeline of ICL products with regulators, which notably included a European submission of data from our multi-site clinical trial for our EDOF lens for Presbyopia which met the clinical trial primary endpoint and a revised submission to the FDA for a least burdensome pathway forward encompassing a clinical trial for our EVO family of lenses in the U.S.”

Financial Overview – Q2 2019

Net sales were $39.7 million for the second quarter of 2019, up 17% as compared to $33.9 million reported in the prior year quarter. The sales increase was driven by ICL revenue and unit growth of 26% and 34%, respectively, which was partially offset by an anticipated decrease in other product sales, which declined 21% as compared to the prior year quarter. Currency, primarily the Euro, negatively impacted reported net sales by approximately $0.6 million in the second quarter. Adjusting for the impact of currency, net sales in the second quarter of 2019 were $40.3 million, representing 19% growth over the prior year quarter.

Gross profit margin for the second quarter of 2019 was 75.4% compared to the prior year period of 74.4%. The 100 basis point increase in gross profit margin for the quarter is primarily due to favorable product mix resulting from increased sales of ICLs and lower other product sales.

Operating expenses for the quarter increased 14% to $25.3 million compared to the prior year quarter of $22.2 million. General and administrative expenses were $7.5 million compared to the prior year quarter of $6.2 million. The increase in general and administrative expenses was due to increased headcount and salary-related expenses, including stock-based compensation and increased facility costs and professional fees. Marketing and selling expenses were $11.7 million compared to the prior year quarter of $10.7 million. The increase in marketing and selling expenses was due to increased headcount and salary-related expenses including stock-based compensation, increased travel expenses and continued investments in digital, strategic, and consumer marketing. Research and development expenses were $6.1 million compared to the prior year quarter of $5.3 million. The increase in research and development expenses is due to an increase in headcount and salary-related expenses, including stock-based compensation.

Operating income margin for the second quarter of 2019 increased 270 basis points to 11.6% as compared to the prior year operating income of 8.9%. The increase in operating income margin is attributable to higher gross margin and lower total operating expense as a percentage of sales in the second quarter of 2019 as compared to the prior year quarter.

Net income for the second quarter of 2019 was $3.9 million or approximately $0.08 per share compared with net income of $1.8 million or $0.04 per share for the prior year quarter. Non-GAAP Adjusted Net Income for the second quarter of 2019 was $6.5 million or $0.14 per share compared to $3.9 million or $0.09 per share for the prior year quarter. The reconciliation between GAAP and non-GAAP financial information is provided in the financial tables included with this release.

Cash, cash equivalents, and restricted cash at June 28, 2019 totaled $103.3 million, compared to $104.0 million at the end of the fourth quarter of 2018. The Company generated $3.5 million in cash from operations in the second quarter.

Conference Call

The Company will host a conference call and webcast today, Wednesday, July 31, 2019 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 7270219), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Conference ID 7270219) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 855-859-2056 for domestic callers and 404-537-3406 for international callers. An archived webcast will also be available at www.staar.com.

Use of Non-GAAP Financial Measures

This press release includes supplemental non-GAAP financial information, which STAAR believes investors will find helpful in understanding its operating performance. “Adjusted Net Income” and “Adjusted Net Income Per Share” exclude the following items that are included in “Net Income” as calculated in accordance with U.S. generally accepted accounting principles (“GAAP”): gain or loss on foreign currency transactions and stock-based compensation expenses. Management believes that “Adjusted Net Income” and “Adjusted Net Income Per Share” are useful to investors in gauging the outcome of the key drivers of the business performance: the ability to increase sales revenue and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which management has control.

Management has also excluded gains and losses on foreign currency transactions because of the significant fluctuations that can result from period to period as a result of market driven factors. Stock-based compensation expenses consist of expenses for stock options and restricted stock under the Financial Accounting Standards Board’s Accounting Standards Codification (ASC) 718. In calculating Adjusted Net Income and Adjusted Net Income Per Share, STAAR excludes these expenses because they are non-cash expenses and because of the considerable judgment involved in calculating their values. In addition, these expenses tend to be driven by fluctuations in the price of our stock and not by the same factors that generally affect our other business expenses.

The Company also uses Constant Currency as a Non-GAAP financial measure to exclude the effects of currency fluctuations on net sales. The Company conducts a significant part of its activities outside the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and euros. The exchange rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on the Company’s results when reported in U.S. dollars. In order to compare the Company's performance from period to period without the effect of currency, the Company will apply the same average exchange rate applicable in the prior period, or the "constant currency" rate to sales or expenses in the current period as well. Because changes in currency are outside of the control of the Company and its managers, management finds this non-GAAP measure useful in determining the long-term progress of its initiatives and determining whether its managers are achieving their performance goals. The Company believes that the non-GAAP constant-currency sales results measures provided in this press release are similarly useful to investors to give insight on long term trends in the Company's performance without the external effect of changes in relative currency values. The table below shows sales results calculated in accordance with GAAP, the effect of currency, and the resulting non-GAAP measure expressed in constant currency.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, including those relating to the plans, strategies, and objectives of management for 2019 or prospects for achieving such plans, expectations for sales, revenue, or earnings, product safety or effectiveness, the status of our pipeline of ICL products with regulators, including our EDOF lens for Presbyopia and our EVO family of lenses in the U.S., and any statements of assumptions underlying any of the foregoing, including those relating to our product pipeline and market expansion activities. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company’s Annual Report on Form 10-K for the year ended December 28, 2018 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events.

These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before approval, or to take enforcement action; potential international trade disputes; and the willingness of surgeons and patients to adopt a new or improved product and procedure. The Visian ICL with CentraFLOW, now known as EVO Visian ICL, is not yet approved for sale in the United States.

Consolidated Balance Sheets
(in 000's)
Unaudited
June 28, 2019December 28, 2018
ASSETS
Current assets:
Cash and cash equivalents

$

103,251

 

$

103,877

 

Accounts receivable trade, net

 

32,962

 

 

25,946

 

Inventories, net

 

16,328

 

 

16,704

 

Prepayments, deposits, and other current assets

 

6,367

 

 

5,045

 

Total current assets

 

158,908

 

 

151,572

 

Property, plant, and equipment, net

 

13,382

 

 

11,451

 

Finance lease right-of-use assets, net

 

2,338

 

 

-

 

Operating lease right-of-use assets, net

 

7,219

 

 

-

 

Intangible assets, net

 

261

 

 

243

 

Goodwill

 

1,786

 

 

1,786

 

Deferred income taxes

 

1,355

 

 

1,278

 

Other assets

 

713

 

 

1,009

 

Total assets

$

185,962

 

$

167,339

 

 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Line of credit

$

2,854

 

$

3,780

 

Accounts payable

 

8,097

 

 

6,524

 

Obligations under finance leases

 

960

 

 

1,098

 

Obligations under operating leases

 

2,766

 

 

-

 

Allowance for sales returns

 

3,263

 

 

2,895

 

Other current liabilities

 

10,771

 

 

13,431

 

Total current liabilities

 

28,711

 

 

27,728

 

Obligations under finance leases

 

580

 

 

459

 

Obligations under operating leases

 

4,580

 

 

-

 

Deferred income taxes

 

1,406

 

 

1,022

 

Asset retirement obligations

 

212

 

 

206

 

Deferred rent

 

-

 

 

188

 

Pension liability

 

6,138

 

 

5,310

 

Total liabilities

 

41,627

 

 

34,913

 

 
Stockholders' equity:
Common stock

 

445

 

 

442

 

Additional paid-in capital

 

296,063

 

 

289,584

 

Accumulated other comprehensive loss

 

(1,602

)

 

(1,320

)

Accumulated deficit

 

(150,571

)

 

(156,280

)

Total stockholders' equity

 

144,335

 

 

132,426

 

Total liabilities and stockholders' equity

$

185,962

 

$

167,339

 

>td rowspan="1"###Net sales

Consolidated Statements of Income
(In 000's except for per share data)
Unaudited
 
>td rowspan="1">Six-Months Ended
>td rowspan="2"###June 28, 2019>td rowspan="2"###June 29, 2018Fav (Unfav)>td rowspan="2"###June 28, 2019>td rowspan="2"###June 29, 2018Fav (Unfav)
SalesSalesAmount>td rowspan="1"###SalesSalesAmount

100.0

###p#<

$

39,664

100.0

###p#<

$

33,905

 

$

5,759

 

17.0

###p#<

100.0

###p#<

$

72,247

 

100.0

###p#<

$

60,998

 

$

11,249

 

18.4

###p#<
 
Cost of sales

24.6

###p#<

 

9,765

25.6

###p#<

 

8,678

 

 

(1,087

)

-12.5

###p#<

25.1

###p#<

 

18,168

 

26.8

###p#<

 

16,340

 

 

(1,828

)

-11.2

###p#<
 
Gross profit

75.4

###p#<

 

29,899

74.4

###p#<

 

25,227

 

 

4,672

 

18.5

###p#<

74.9

###p#<

 

54,079

 

73.2

###p#<

 

44,658

 

 

9,421

 

21.1

###p#<
 
Selling, general and administrative expenses:
General and administrative

18.9

###p#<

 

7,508

18.3

###p#<

 

6,196

 

 

(1,312

)

-21.2

###p#<

19.9

###p#<

 

14,345

 

19.6

###p#<

 

11,967

 

 

(2,378

)

-19.9

###p#<
Marketing and selling

29.5

###p#<

 

11,682

31.4

###p#<

 

10,659

 

 

(1,023

)

-9.6

###p#<

30.2

###p#<

 

21,825

 

29.7

###p#<

 

18,113

 

 

(3,712

)

-20.5

###p#<
Research and development

15.4

###p#<

 

6,098

15.8

###p#<

 

5,346

 

 

(752

)

-14.1

###p#<

16.3

###p#<

 

11,733

 

17.6

###p#<

 

10,753

 

 

(980

)

-9.1

###p#<
Total selling, general, and administrative expenses

63.8

###p#<

 

25,288

65.5

###p#<

 

22,201

 

 

(3,087

)

-13.9

###p#<

66.4

###p#<

 

47,903

 

66.9

###p#<

 

40,833

 

 

(7,070

)

-17.3

###p#<
 
Operating income

11.6

###p#<

 

4,611

8.9

###p#<

 

3,026

 

 

1,585

 

52.4

###p#<

8.5

###p#<

 

6,176

 

6.3

###p#<

 

3,825

 

 

2,351

 

61.5

###p#<
 
Other income (expense):
Interest Income (expense), net

0.7

###p#<

 

259

-0.1

###p#<

 

(24

)

 

283

 

1179.2

###p#<

0.7

###p#<

 

530

 

-0.1

###p#<

 

(36

)

 

566

 

1572.2

###p#<
Gain (loss) on foreign currency transactions

0.0

###p#<

 

11

-1.5

###p#<

 

(520

)

 

531

 

102.1

###p#<

-0.3

###p#<

 

(237

)

-0.9

###p#<

 

(597

)

 

360

 

60.3

###p#<
Royalty income

0.4

###p#<

 

163

0.5

###p#<

 

149

 

 

14

 

9.4

###p#<

0.5

###p#<

 

334

 

0.5

###p#<

 

306

 

 

28

 

9.2

###p#<
Other income, net

0.0

###p#<

 

1

0.0

###p#<

 

4

 

 

(3

)

-75.0

###p#<

0.1

###p#<

 

98

 

0.0

###p#<

 

21

 

 

77

 

366.7

###p#<
Total other income (expense), net

1.1

###p#<

 

434

-1.1

###p#<

 

(391

)

 

825

 

211.0

###p#<

1.0

###p#<

 

725

 

-0.5

###p#<

 

(306

)

 

1,031

 

336.9

###p#<
 
Income before provision for income taxes

12.7

###p#<

 

5,045

7.8

###p#<

 

2,635

 

 

2,410

 

91.5

###p#<

9.5

###p#<

 

6,901

 

5.8

###p#<

 

3,519

 

 

3,382

 

96.1

###p#<
 
Provision for income taxes

2.9

###p#<

 

1,131

2.4

###p#<

 

805

 

 

(326

)

-40.5

###p#<

2.2

###p#<

 

1,620

 

1.8

###p#<

 

1,106

 

 

(514

)

-46.5

###p#<
 
Net income

9.8

###p#<

$

3,914

5.4

###p#<

$

1,830

 

$

2,084

 

113.9

###p#<

7.3

###p#<

$

5,281

 

4.0

###p#<

$

2,413

 

$

2,868

 

118.9

###p#<
 
Net income per share - basic

$

0.09

$

0.04

 

$

0.12

 

$

0.06

 

Net income per share - diluted

$

0.08

$

0.04

 

$

0.11

 

$

0.06

 

 
Weighted average shares outstanding - basic

 

44,479

 

41,723

 

 

44,357

 

 

41,568

 

Weighted average shares outstanding - diluted

 

46,733

 

43,999

 

 

46,842

 

 

43,654

 

Consolidated Statements of Cash Flows
(in 000's)
Unaudited
>td >Six-Months Ended
June 28, 2019June 29, 2018June 28, 2019June 29, 2018
 
Cash flows from operating activities:
Net income

$

3,914

 

$

1,830

 

$

5,281

 

$

2,413

 

Adjustments to reconcile net income to net cash provided by (used in) operating
activities:
Depreciation of property and equipment

 

761

 

 

619

 

 

1,983

 

 

1,168

 

Amortization of long-lived intangibles

 

9

 

 

8

 

 

17

 

 

17

 

Deferred income taxes

 

314

 

 

266

 

 

393

 

 

358

 

Change in net pension liability

 

84

 

 

72

 

 

203

 

 

159

 

Stock-based compensation expense

 

2,579

 

 

1,598

 

 

5,220

 

 

2,899

 

Loss on disposal of property and equipment

 

-

 

 

-

 

 

-

 

 

6

 

Provision for sales returns and bad debts

 

2

 

 

130

 

 

(32

)

 

644

 

Inventory provision

 

332

 

 

247

 

 

787

 

 

753

 

Changes in working capital:
Accounts receivable

 

(5,979

)

 

(3,635

)

 

(6,533

)

 

(6,390

)

Inventories

 

113

 

 

(1,140

)

 

106

 

 

(1,536

)

Prepayments, deposits and other current assets

 

1,163

 

 

(159

)

 

(1,154

)

 

(889

)

Accounts payable

 

748

 

 

(1,082

)

 

563

 

 

956

 

Other current liabilities

 

(563

)

 

1,022

 

 

(2,626

)

 

1,748

 

Net cash provided by (used in) operating activities

 

3,477

 

 

(224

)

 

4,208

 

 

2,306

 

 
Cash flows from investing activities:
Acquisition of property and equipment

 

(2,398

)

 

(304

)

 

(4,601

)

 

(1,269

)

Increase in patents and licenses

 

-

 

 

-

 

 

(30

)

 

-

 

Net cash used in investing activities

 

(2,398

)

 

(304

)

 

(4,631

)

 

(1,269

)

 
Cash flows from financing activities:
Repayment on line of credit

 

(500

)

 

-

 

 

(999

)

 

-

 

Repayment of finance lease obligations

 

(316

)

 

(501

)

 

(681

)

 

(881

)

Proceeds from vested restricted stock and exercise of stock options

 

488

 

 

1,953

 

 

1,112

 

 

2,407

 

Net cash provided by (used in) financing activities

 

(328

)

 

1,452

 

 

(568

)

 

1,526

 

 
Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

267

 

 

(449

)

 

243

 

 

163

 

 
Increase (decrease) in cash, cash equivalents and restricted cash

 

1,018

 

 

475

 

 

(748

)

 

2,726

 

Cash, cash equivalents and restricted cash, at beginning of the period

 

102,233

 

 

20,892

 

 

103,999

 

 

18,641

 

Cash, cash equivalents and restricted cash, at end of the period

$

103,251

 

$

21,367

 

$

103,251

 

$

21,367

 

>td ###Sales by Region

Global Sales
(in 000's)
Unaudited
 
>td >Six-Months Ended
June 28, 2019June 29, 2018>td ###June 28, 2019June 29, 2018
Fav (Unfav)Fav (Unfav)
North America

6.2

###p#<

$

2,442

6.7

###p#<

$

2,275

7.3

###p#<

6.4

###p#<

$

4,640

7.1

###p#<

$

4,354

6.6

###p#<
Europe, Middle East, Africa, Latin America

19.6

###p#<

 

7,786

23.8

###p#<

 

8,064

-3.4

###p#<

22.2

###p#<

 

16,051

27.2

###p#<

 

16,573

-3.1

###p#<
Asia Pacific

74.2

###p#<

 

29,436

69.5

###p#<

 

23,566

24.9

###p#<

71.4

###p#<

 

51,556

65.7

###p#<

 

40,071

28.7

###p#<
Total Sales

100.0

###p#<

$

39,664

100.0

###p#<

$

33,905

17.0

###p#<

100.0

###p#<

$

72,247

100.0

###p#<

$

60,998

18.4

###p#<
 
Core Product Sales
ICLs

86.8

###p#<

$

34,432

80.5

###p#<

$

27,292

26.2

###p#<

86.1

###p#<

$

62,218

79.4

###p#<

$

48,450

28.4

###p#<
Other Product Sales
Ions

9.8

###p#<

 

3,874

12.3

###p#<

 

4,186

-7.5

###p#<

10.9

###p#<

 

7,891

13.5

###p#<

 

8,244

-4.3

###p#<
Injector Parts and Other

3.4

###p#<

 

1,358

7.2

###p#<

 

2,427

-44.0

###p#<

3.0

###p#<

 

2,138

7.1

###p#<

 

4,304

-50.3

###p#<
Total Other Sales

13.2

###p#<

 

5,232

19.5

###p#<

 

6,613

-20.9

###p#<

13.9

###p#<

 

10,029

20.6

###p#<

 

12,548

-20.1

###p#<
Total Sales

100.0

###p#<

$

39,664

100.0

###p#<

$

33,905

17.0

###p#<

100.0

###p#<

$

72,247

100.0

###p#<

$

60,998

18.4

###p#<
Reconciliation of Non-GAAP Financial Measure
Adjusted Net Income and Net Income Per Share
(in 000's)
Unaudited>td rowspan="1">Six-Months Ended
June 28, 2019June 29, 2018June 28, 2019June 29, 2018
 
Net income (as reported)

$

3,914

 

$

1,830

$

5,281

$

2,413

Less:
Foreign currency impact

 

(11

)

 

520

 

237

 

597

Stock-based compensation expense

 

2,579

 

 

1,598

 

5,220

 

2,899

Net income (adjusted)

$

6,482

 

$

3,948

$

10,738

$

5,909

 
Net income per share, basic (as reported)

$

0.09

 

$

0.04

$

0.12

$

0.06

Foreign currency impact

 

-

 

 

0.01

 

-

 

0.01

Stock-based compensation expense

 

0.06

 

 

0.04

 

0.12

 

0.07

Net income per share, basic (adjusted)

$

0.15

 

$

0.09

$

0.24

$

0.14

 
Net income per share, diluted (as reported)

$

0.08

 

$

0.04

$

0.11

$

0.06

Foreign currency impact

 

-

 

 

0.01

 

0.01

 

0.01

Stock-based compensation expense

 

0.06

 

 

0.04

 

0.11

 

0.07

Net income per share, diluted (adjusted)

$

0.14

 

$

0.09

$

0.23

$

0.14

 
Weighted average shares outstanding - Basic

 

44,479

 

 

41,723

 

44,357

 

41,568

Weighted average shares outstanding - Diluted

 

46,733

 

 

43,999

 

46,842

 

43,654

Note: Net income per share (adjusted), basic and diluted, may not add due to rounding

>td >td

Reconciliation of Non-GAAP Financial Measure
Constant Currency Sales
(in 000's)
Unaudited
>td rowspan="1">
June 28, 2019Effect ofConstantJune 29, 2018As ReportedConstant Currency
SalesCurrencyCurrency$ Change>td ###$ Change

$

34,432

$

509

$

34,941

$

27,292

$

7,140

 

26.2

>p#<

$

7,649

 

28.0

###p#<
IOL

 

3,874

 

94

 

3,968

 

4,186

 

(312

)

-7.5

###p#<

 

(218

)

-5.2

###p#<
Other

 

1,358

 

7

 

1,365

 

2,427

 

(1,069

)

-44.0

###p#<

 

(1,062

)

-43.8

###p#<
Total Sales

$

39,664

$

610

$

40,274

$

33,905

$

5,759

 

17.0

###p#<

$

6,369

 

18.8

###p#<
 
Six Months Ended
June 28, 2019Effect ofConstantJune 29, 2018As ReportedConstant Currency
SalesCurrencyCurrency$ Change>td ###$ Change

$

62,218

$

1,049

$

63,267

$

48,450

$

13,768

 

28.4

>p#<

$

14,817

 

30.6

###p#<
IOL

 

7,891

 

243

 

8,134

 

8,244

 

(353

)

-4.3

###p#<

 

(110

)

-1.3

###p#<
Other

 

2,138

 

10

 

2,148

 

4,304

 

(2,166

)

-50.3

###p#<

 

(2,156

)

-50.1

###p#<
Total Sales

$

72,247

$

1,302

$

73,549

$

60,998

$

11,249

 

18.4

###p#<

$

12,551

 

20.6

###p#<

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20190731005904/en/

Source: STAAR Surgical Company

Investors & Media
Brian Moore
Sr. Director, Investor, Media Relations and Corporate Development
(626) 303-7902, Ext. 3023
[email protected]